XML 27 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Shared-Based Compensation
9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Shared-Based Compensation

Note 9. Shared-Based Compensation

During the three and nine months ended September 30, 2016 and 2015, approximately $0.9 million and $3.6 million in 2016 and $1.1 million and $2.9 million in 2015, respectively, of compensation expense was recognized in selling, general and administrative expense for all share-based awards. During the nine months ended September 30, 2016, we granted 152,510 restricted stock awards, 167,000 option awards, and 202,330 performance based awards to non-executive directors, officers and certain other key employees. During the nine months ended September 30, 2015, we granted 114,475 restricted stock awards, 54,600 option awards and 71,550 performance based awards to non-executive directors, officers and certain other key employees.

 

The shares of restricted stock granted during the nine months ended September 30, 2016, vest pro-rata over three years for officers and certain other key employees and over one year for non-executive directors. During the three and nine months ended September 30, 2016 and 2015, we incurred $0.4 million and $2.0 million in 2016 and $0.6 million and $1.7 million in 2015, respectively, in expense related to restricted stock. The fair value of the shares issued was determined by using the grant date closing price of our common stock.

The performance share units granted during the nine months ended September 30, 2016 will be satisfied in the form of shares of common stock during 2019 if certain performance and/or market conditions are met. We are recognizing the compensation expense over the three-year period in which the performance and market conditions are measured. During the three and nine months ended September 30, 2016 and 2015, we incurred $0.3 million and $0.9 million in 2016, and $0.3 million and $0.5 million in 2015, respectively, in expense related to performance share units. The fair value of the performance share units issued was determined by using the grant date closing price of our common stock for the units with a performance condition and a Monte Carlo valuation model for the units that have a market condition.

We incurred $0.2 million and $0.7 million in 2016 and $0.2 million and $0.7 million in 2015 of stock option expense in the three and nine months ended September 30, 2016 and 2015, respectively. The weighted average grant date fair value of options granted during the nine months ended September 30, 2016, was $5.02. The fair value of our options cannot be determined by market value, because our options are not traded in an open market. Accordingly, we utilized the Black Scholes financial pricing model to estimate the fair value. The weighted average assumptions relevant to determining the fair value of the 2016 stock option grants are below:

 

     2016
Stock Option
Awards
 

Term

     6 years   

Risk free interest rate

     1.43

Dividend yield

     2.48

Expected volatility

     59.23

Expected forfeiture rate

     3.00

The following table provides a reconciliation of option activity for the nine months ended September 30, 2016:

 

                   Weighted-         
            Weighted-      Average         
            Average      Remaining         
            Exercise      Contractual      Aggregate  

Options

   Shares (000)      Price      Term (years)      Intrinsic Value  

Outstanding at January 1, 2016

     1,034       $ 12.09         

Granted

     167       $ 11.31         

Exercised

     (242    $ 10.54         

Forfeited or expired

     (33    $ 17.38         
  

 

 

    

 

 

       

Outstanding at September 30, 2016

     926       $ 12.16         6.1       $ 6,092 (1)
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable at September 30, 2016

     714       $ 11.54         5.2       $ 1,086 (1)
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) The intrinsic value is the amount by which the market price of our stock was greater than the exercise price of any individual option grant at September 30, 2016.